The most-favored hypothesis associates the appearance of chronic pulmonary manifestations with the common use of biological drugs acting on IL-1 and IL-6 for the treatment of sJIA. This evidence concerns the gene IL6 and systemic-onset juvenile idiopathic arthritis.